Value Sense
CABA
Cabaletta Bio, Inc. (CABA)
Last Price$1.7(7.7%)
Market Cap$85.9M
Intrinsic value score
6/10
Good
Intrinsic value
$10.5
DCF value - N/A Relative value - $10.5
Undervalued
528.8%
LTM P/E
(0.8x)
Peer set median (28.8x)
Discount rate
9.4%
CABA
is 528.8% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

CABA Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 CABA Relative Value is $11.0, which is undervalued by 558.1%, compared to current share price of $1.7.
DCF Value vs Current Share Price
As of Mar 03, 2025 CABA DCF Value is N/A, which is undervalued by N/A, compared to current share price of $1.7.
Methodology
Price per share, $
CABA
Intrinsic value$10.5
Undervalued by528.8%
Current share price
1.7
Relative value
11.0
DCF value
not available

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

CABA Historical Intrinsic Value

Crunching data... Almost there!

CABA vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Cabaletta Bio, Inc. logo
Cabaletta Bio, Inc.CABA
528.8%
N/A
(6.8%)
N/A
Median Peer Set
18.9%
(47.6%)
0.4%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(97.4%)
N/A
(68.7%)
N/A
argenx SE logo
argenx SEARGX
(82.5%)
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
(61.6%)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
(59.6%)
11.7%
N/A
(4.9%)
Incyte Corporation logo
Incyte CorporationINCY
(33.6%)
14.8%
(94.0%)
0.8%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
(32.9%)
24.9%
142.8%
34.8%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
37.8%
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
48.0%
8.3%
10.4%
31.1%
BioNTech SE logo
BioNTech SEBNTX
48.6%
(77.4%)
(89.7%)
24.4%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
1,137.3%
73.7%
(56.5%)
(35.9%)

Explore more intrinsic value tools hub for CABA

DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate

FAQ

What is Cabaletta Bio, Inc. intrinsic value?

As of Mar 03, 2025, Cabaletta Bio, Inc. Intrinsic Value is $10.5. This suggests it may be undervalued by 528.8% compared to its current price of around $1.7.

What is Cabaletta Bio, Inc. DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Cabaletta Bio, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $1.7, using a discount rate of 9.4% and terminal growth rate of 3.0%.

Is Cabaletta Bio, Inc. overvalued or undervalued?

Cabaletta Bio, Inc. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $10.5, compared to a market price of around $1.7. This suggests a potential undervaluation of 528.8%.